Walgreens Boots Alliance FY2024 Maintains U.S. Healthcare Adjusted EBITDA To Be Breakeven At The Midpoint Of The Guidance Range Of ($50)M-$50M
Portfolio Pulse from Benzinga Newsdesk
Walgreens Boots Alliance (WBA) has announced that for FY2024, it expects its U.S. Healthcare Adjusted EBITDA to be breakeven at the midpoint of its guidance range, which spans from a loss of $50 million to a gain of $50 million.
March 28, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Walgreens Boots Alliance expects its U.S. Healthcare Adjusted EBITDA for FY2024 to be breakeven at the midpoint of its guidance range of ($50)M-$50M.
The announcement indicates a cautious but not negative outlook for WBA's U.S. Healthcare segment for FY2024. The breakeven expectation at the midpoint suggests that while there are challenges, there's also potential for stability. This neutral guidance is likely to have a similarly neutral short-term impact on WBA's stock price, as it neither significantly exceeds nor falls short of market expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100